Surf Bio to Showcase Innovative Biologic Delivery Technology
Surf Bio to Participate in Notable Virtual Forum
Company to Highlight SnapShot™ Technology for High-Concentration, Subcutaneous Biologic Delivery
PALO ALTO, Calif. — Surf Bio, a biopharmaceutical company revolutionizing how antibodies and biologics are delivered, announced that Bryan Mazlish, the CEO, will be attending the prestigious 5th Annual Needham Private Biotech and MedTech Company Virtual 1×1 Forum. This event is scheduled for mid-October and aims to strengthen connections between innovators and investors in the biotech sector.
During the forum, Mr. Mazlish will engage in one-on-one discussions with registered investors where he will highlight Surf Bio's strategic vision and developmental progress, particularly focusing on their proprietary SnapShot™ technology platform. This innovative approach is crafted to facilitate subcutaneous administration of extraordinarily high doses of monoclonal antibodies (mAbs) and various other biologics. Given the ever-growing pipeline of biologics, solutions such as SnapShot™ address key challenges around access, production capabilities, and the overall capacity of healthcare systems.
Here are the details of the upcoming conference:
Conference Details
Event: 5th Annual Needham Private Biotech and MedTech Company Virtual 1×1 Forum
Date: October 14-15, 2025
Registration: Interested parties can find registration information online.
About Surf Bio
Surf Bio is pioneering advancements in the biopharmaceutical field, particularly in transforming the administration of antibodies and biologics. Their cutting-edge SnapShot™ technology, driven by a proprietary polymer, allows for the creation of ultra-high concentration formulations of monoclonal antibodies. These can be delivered via a single, standard autoinjector shot. The company has gathered substantial in-vitro and in-vivo safety and efficacy data supporting that SnapShot™ enables drug developers to create highly concentrated, subcutaneous formulations of novel mAbs and other biologics.
For additional information on Surf Bio and their innovative offerings, please visit their official website.
Contact Information
For media inquiries, please reach out to: Tiberend Strategic Advisors, Inc.
Eric Reiss
Email: [Contact]
Frequently Asked Questions
What is SnapShot™ technology?
SnapShot™ technology is Surf Bio's proprietary platform designed for high-concentration, subcutaneous delivery of biologics.
Who is Bryan Mazlish?
Bryan Mazlish is the CEO of Surf Bio, leading the company’s strategic initiatives and innovations.
When will the forum take place?
The 5th Annual Needham Private Biotech and MedTech Company Virtual 1×1 Forum is scheduled for October 14-15, 2025.
How can I learn more about Surf Bio?
More information can be found on Surf Bio's official website, detailing their technologies and initiatives.
What are the benefits of SnapShot™ technology?
SnapShot™ technology improves patient access and reduces burdens on healthcare systems while ensuring efficient drug delivery.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.